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ABBREVIATIONS 
CLD    Chronic liver disease. 
QTc    Corrected QT interval. 
QTcd    Corrected QT dispersion. 
QTcmax   Corrected QT maximium. 
QTcmin   Corrected QT minimum 
MELD   Model for End Stage Liver Disease. 
NASH   Nonalcoholic steatohepatitits 
NAFLD   Nonalcoholic fatty liver disease 
PT    Prothrombin time 
INR    International normalized ratio 
AST    Aspartate transaminase 
ALT    Alanine transaminase 
ALP    Alkaline phosphatase 
ANTI-LKM   Anti liver kidney microsomal antibody 
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ANA    Anti-nuclear antibody 
ANTI-SMA   Anti smooth muscle antibody 
PBC    Primary biliary cirrhosis 
PSC    Primary sclerosing cholangitis 
LFT    Liver function tests 
ECG    Electrocardiogram 
USG    Ultrasonogram 
ms    milliseconds 
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INTRODUCTION 
                                       Chronic liver disease is increasing in frequency 
worldwide and is among the top ten causes of death at present. Moreover 
those who suffer from chronic liver disease needs repeated hospitalization 
and prolonged medical attention, which leaves them physically, and 
psychologically devastated. The mortality rate is also very high; the median 
survival in patients with decompensated chronic liver disease is about two 
years. Patients usually die of complications of liver disease such as hepatic 
encephalopathy, bleeding varices, hepatorenal syndrome, infections, but 
sudden death due to cardiac arrthymias has also been frequently reported. 
                                         Several studies has demonstrated that QT interval 
in standard electrocardiogram is prolonged in patients with chronic liver 
disease which may lead to sudden death and poor survival of chronic liver 
disease patients. The QT interval reflects the total duration of myocardial 
depolarization and repolarization. The various factors implicated in QT 
prolongation are increased bilirubin levels, low testosterone levels, 
autonomic neuropathy leading to decreased sensitivity of baroreceptor and 
heart rate variability, high sympathetic activity, electrolyte imbalance, 
however patients with alcohol related chronic liver disease and those who 
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are in Child Pugh’s class C clearly have prolonged QT interval in 
electrocardiogram. 
Corrected QT dispersion (QTcd) has been defined as inter lead QT interval 
variability (difference between maximum and minimum QT interval). 
Increased QTcd is a direct reflection of disparity in myocardial recovery, 
and determination of QTcd may help to predict arrhythmic events in chronic 
liver disease patients. Several studies in the past has documented 
prolongation of QT interval in chronic liver disease, unfortunately very few 
studies have been done regarding QT dispersion in chronic liver disease. In 
this study we aim to analyze corrected QT dispersion and its correlation with 
the severity of chronic liver disease. 
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AIMS AND OBJECTIVES 
 To study the relationship between corrected QT dispersion and 
severity of chronic liver disease based on Child-Pugh’s classification. 
 To evaluate the usefulness of corrected QT dispersion in assessing 
severity of chronic liver disease. 
 To study the relationship between corrected QT dispersion and 
various factors implicated in prolongation of QT interval. 
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REVIEW OF LITERATURE 
CHRONIC LIVER DISEASE: 
Chronic liver disease is a term used to define a disease process that leads to 
progressive destruction of liver parenchyma and regeneration that leads to 
fibrosis and cirrhosis. It is a progressive fibrosing and nodular condition that 
disrupts the architecture of entire liver. 
Chronic liver disease and cirrhosis is the twelfth leading cause of death in 
US (12), and its burden is increasing worldwide. Up to forty percentages of 
patients with cirrhosis were asymptomatic until the occurrence of 
decompensation in the form of bleeding varices, hepatic encephalopathy, 
and spontaneous bacterial peritonitis. Previously fibrosis and cirrhosis was 
thought to irreversible but new evidence suggests that fibrosis may be 
reversible in some but not all patients with chronic hepatitis B, 
hemochromatosis(9).  
Cirrhosis represents an advanced stage of fibrosis and characterized by 
distortion of hepatic parenchymal anatomy and formation of regenerative 
nodules. The pathogenesis of fibro genesis is activation of stellate cell which 
is the cardinal feature of hepatic fibrosis. The stellate cells lies within the 
space of disse is in direct contact with the hepatocytes, inflammatory cells, 
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endothelial cells, they store vitamin A in normal liver, about 40- 70% of 
body retinoid is stored in stellate cell. Scar formation is mediated through 
increased proliferation of hepatic stellate cells, chemo taxis, fibro genesis, 
altered degradation of collagen matrix and interaction between hepatic 
stellate cells and immune system and secretion of inflammatory mediators. 
The extracellular matrix during fibrogenesis consists of collagen and 
glycoproteins and hyaluronic acid. TGF beta1 is the central molecule in 
mediating fibrogenesis and TIMP-1 plays a huge role in initiation, 
progression and regression of fibrogenesis. The importance of TIMP-1 can 
be understood from the fact that overexpression of human TIMP-1 in mice 
increased CCL4 induced fibrosis by seven fold. 
ETIOLOGY AND RISK FACTORS: 
Alcoholic liver disease is the most common worldwide but in developed 
countries it is being overtaken by Hepatitis C and Hepatitis B. 
NAFLD AND NASH (Nonalcoholic fatty liver disease and Nonalcoholic 
steatohepatitits): around two to three percentage of those with NAFLD will 
progress to NASH of which about ten percentages will progress to cirrhosis. 
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RISK FACTORS: 
Heavy alcohol consumption 
Health care professionals 
Obesity 
Tattooing 
Unprotected sex 
Toxic and chemical exposures 
Certain medications 
IV drug abusers sharing intravenous needles 
ETIOLOGY: 
Alcoholic liver disease 
Viral: 
 Chronic hepatitis C 
 Chronic hepatitis B 
 Cytomegalovirus 
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 Epstein Barr virus 
Metabolic: 
 NAFLD/NASH 
 Hemochromatosis 
 Wilson’s disease 
 Diabetes mellitus 
 Alpha 1 anti-trypsin deficiency 
 Cystic fibrosis 
 Tyrosinosis 
 Hereditary fructose intolerance 
 Glycogen storage diseases 
Drug induced: 
 Amiodarone 
 Methotrexate 
 Nitrofurantoin 
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Biliary cirrhosis 
 Primary biliary cirrhosis 
 Primary sclerosing cholangitis 
 Autoimmune cholangiopathy 
Cardiac: 
 Chronic right heart failure 
 Tricuspid regurgitation 
Cryptogenic 
 
CLINICAL FEATURES: 
Patient with chronic liver disease may be identified in the following ways (3): 
1. Patients may be identified on routine clinical examination. 
2. They might have undergone laboratory/radiological imaging or some 
procedures which incidentally found out the presence of chronic liver 
disease. 
3. They may present in a decompensated state. 
4. Some patients may never come to clinical attention.(4) 
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HISTORY: 
This should include questions to identify risk factors for chronic liver 
disease like history of alcohol intake, hepatitis, jaundice, diabetes, illicit 
drug use, blood transfusion, any surgery, family history of liver diseases and 
autoimmune conditions. 
Questioning should also include those related to symptoms of chronic liver 
disease like fatigue, pedal edema, weight loss, confusion, bleeding tendency. 
Symptoms may vary from asymptomatic to overt features of 
decompensation. Patients with chronic liver disease due to hepatitis C may 
have muscle wasting, large ascites and overt hepatic encephalopathy but 
only mild jaundice while patients with chronic liver disease due to primary 
biliary cirrhosis may have deep icterus but no muscle wasting. Patients may 
experience fatigue, anorexia, weight loss. Cutaneous manifestations may 
include jaundice, spider naevi, paper money skin, palmar erythema, white 
nails, disappearance of lunulae, and finger clubbing. 
Increased conversion of androgens to estrogen occurs in adipose tissue, 
skeletal muscle which may be responsible for loss of axillary and pubic hair, 
gynaecomastia, impotence. Anemia may be due to folate deficiency, 
hemolysis, and hypersplenism. Thrombocytopenia is usually the first marker 
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of hypersplenism. Coagulopathy results from decreased production of 
coagulation factors and diminished absorption of vitamin  
SYMPTOMS: 
 Fatigue, weakness 
 Poor appetite 
 Muscle wasting 
 Jaundice 
 Breast enlargement in men 
 Ascites 
 Parotid gland enlargement 
 Altered sleep pattern, somnolence, 
Pruritus 
Blood vomiting 
 Redness of palms 
 Impotence, loss of libido 
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SIGNS (9) 
Signs may be classified as those associated with etiology and those 
associated with decompensation. 
SIGNS ASSOCIATED WITH ETIOLOGY: 
Alcohol related: 
 Parotid enlargement 
 Dupuytren’s contracture 
 Peripheral neuropathy 
 Cerebellar signs 
 Testicular atrophy 
Wilson’s disease: 
 Kayer Fleischer ring 
 Hepatomegaly 
 Dystonia, tremors, involuntary movements 
Hemochromatosis: 
 Increased pigmentation 
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 Hepatomegaly 
NASH: 
 Xanthomas, xanthelesma 
 Corneal arcus 
Viral hepatitis: 
 Tattoo marks, injection marks 
Right heart failure: 
 Peripheral edema 
 Elevated JVP 
SIGNS OF DECOMPENSATION: 
 Icterus 
 Ascites  
 Peripheral edema 
 Ecchymosis 
 Asterixis 
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 Encephalopathy 
 Bleeding varices 
 Spider angiomata 
 Cruveilheir Baumgarten murmur 
 Fetor hepaticus 
 Caput medusae 
COMPLICATIONS (9): 
 Portal hypertension 
 Ascites 
 Hypersplenism 
 Variceal bleeding 
 Hepatorenal syndrome 
 Portopulmonary hypertension 
 Hepatic encephalopathy 
 Hepatopulmonary syndrome 
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 Malignant transformation. 
DIAGNOSIS: 
Many times the presence of chronic liver disease is suggested by laboratory 
investigations. Common laboratory investigations performed under the label 
LFT (liver function tests) are 
 1) Enzyme tests 
  Serum aminotransferases (AST, ALT) 
  Serum alkaline phosphatase 
  Gamma Glutamyl Trans peptidase 
 2) Serum bilirubin 
 3) Assess synthetic function 
  Serum albumin 
  Prothrombin time and INR 
Aminotransferases: 
Both aspartate transaminase and alanine transaminase may be elevated but 
usually <3 times the upper normal limit, but can be normal in advanced 
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stages of liver disease. Chronic liver disease other than alcohol will have 
AST/ALT ratio less than one. 
Alkaline phosphatase: 
Elevated in most forms of chronic liver disease but will be less than three 
times the upper normal limit. High levels are noted in  
1) Primary biliary cirrhosis 
2) Primary sclerosing cholangitis 
Gamma Glutamyl Trans peptidase: 
It is considered moderately specific for alcoholic liver disease because of 
two reasons 
1) Alcohol induces hepatic microsomal GGT synthesis. 
2) Alcohol causes leakage of GGT from hepatocytes. 
Serum bilirubin: 
It may be normal in compensated state but elevated bilirubin indicates fairly 
advanced liver disease. 
In primary biliary cirrhosis elevated bilirubin indicates poor prognosis. 
Serum albumin: 
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As liver function deteriorates albumin levels also decreases as it is solely 
synthesized in liver but hypoalbuminaemia is not specific for chronic liver 
disease as it may be decreased in other conditions like  
1) Nephrotic syndrome 
2) Protein losing enteropathy 
3) Malnutrition 
Prothrombin time: 
Increases as liver disease progresses since coagulation factors are produced 
in liver. 
Serum globulin: 
Elevated levels of globulin are seen in cirrhosis as various antigens are 
shunted away from liver, reach systemic circulation and elicit 
immunological response. Increased levels of IgM are seen in primary biliary 
cirrhosis, increased IgA is seen in alcoholic liver disease. 
Serum sodium: 
Hyponatremia in chronic liver disease patients indicates poor prognosis, and 
is due to high levels of ADH seen in cirrhotic patients. 
Hematological investigations: 
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Anemia: 
May be due to  blood loss 
   Folate deficiency 
   Direct toxicity of alcohol 
   Hemolysis 
   Anemia of chronic disease 
   Hypersplenism 
Thrombocytopenia: 
Due to hypersplenism, but the platelet count doesn’t drop below 50000 cells/ 
mm3. May cause bleeding if associated with coagulopathy. 
Leucopenia, neutropenia: 
Due to hypersplenism and splenic margination. 
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INVESTIGATIONS TO DETERMINE THE ETIOLOGY OF 
CHRONIC LIVER DISEASE: 
Alcoholic liver disease: 
 History of alcohol abuse 
 AST: ALT ratio > 2 due alcohol induced deficiency of pyridoxal 
phosphate 
 Liver biopsy may show features typical of alcoholic hepatitis, 
Mallory’s hyaline, liver cell necrosis. 
Chronic hepatitis C: 
 Anti HCV antibody 
 HCV RNA quantification 
 Liver biopsy to establish the severity of liver disease. 
Chronic hepatitis B: 
 HBsAg 
 HBeAg 
 HBV DNA Quantification 
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NASH: 
 associated features of metabolic syndrome like hyperglycemia, 
hyperlipidemia. 
 Liver biopsy 
Primary biliary cirrhosis: 
 Elevated alkaline phosphatase 
 Anti-mitochondrial antibody is considered to be the hallmark of 
primary biliary cirrhosis 
 ERCP 
Primary sclerosing cholangitis: 
 Associated with inflammatory bowel disease. 
 Contrast cholangiography shows diffuse, focal strictures and dilatation 
of bile ducts giving it a beaded appearance. 
 Anti-smooth muscle antibody (ASMA) 
 Anti-nuclear antibodies 
 Anti-neutrophilic cytoplasmic antibody(ANCA) 
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Autoimmune hepatitis: 
 Increased gamma globulin levels 
 Anti-LKM1 antibody 
 Anti-ALC antibody 
Hemochromatosis: 
 Family history of cirrhosis 
 Increased skin pigmentation 
 Fasting transferrin saturation  
More than 60% in men 
More than 50 % in women 
 Plasma ferritin  
>300mg/dl in men 
  >200mg/dl in women 
 Genetic testing  
 Liver biopsy 
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Wilson’s disease: 
 Kayer Fleisher rings on slit lamp examination. 
 Decreased serum ceruloplasmin. 
 24 hour urinary copper >100mg 
 Copper content >200mg/g of liver tissue in liver biopsy. 
 Haplotype analysis. 
Alpha 1 anti-trypsin deficiency: 
 Decreased serum alpha1 anti-trypsin levels. 
 Genetic testing 
Right sided heart failure: 
 Electrocardiogram 
 Echocardiogram  
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RADIOLOGICAL IMAGING 
Ultrasound abdomen: 
 Provide useful information regarding liver size, echo texture. 
 Useful screening to identify development of HCC (hepatocellular 
carcinoma) in a patient with preexisting cirrhosis. 
Doppler ultrasound: 
 Provides information regarding blood flow in portal vein, hepatic 
veins. 
 Assess size of portal vein, splenic vein. 
 Identify presence of collaterals. 
Computed tomography Abdomen: 
 To assess liver size, shape. 
 To identify liver nodule. 
 To detect HCC. 
MRI Abdomen: 
 Most useful in evaluating the biliary tree 
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 To detect malignancy. 
Transient elastography (9) (Fibro scan): 
 Noninvasive method to assess the stiffness and evaluate liver fibrosis 
and cirrhosis. 
Liver biopsy: 
 The gold standard test to aid in identifying the etiology of chronic 
liver disease. 
 To grade the disease activity. 
 To assess the severity of chronic liver disease. 
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DIAGNOSTIC ALGORITHM: CHRONIC LIVER DISEASE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patients with risk 
factors and/or 
clinical features of 
CLD 
Patient with 
incidental lab or 
imaging abnormality 
consistent with CLD 
Confirm CLD with 
history, physical 
examination 
Obtain LFT and targeted serology to confirm CLD 
Obtain USG Doppler to assess liver size, echo texture and 
to assess potential complication 
Refer for liver biopsy if still in doubt about diagnosis, to 
assess severity of CLD 
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 ASSESSMENT OF SEVERITY AND PROGNOSIS 
Severity may be assessed by  
1) Child Pugh’s scoring system 
2) MELD scoring system 
3) Liver biopsy 
CHILD PUGH’S SCORING SYSTEM: 
Clinical and Lab 
Criteria. 
Points 
1 2 3 
Ascites None Slight (diuretic 
responsive) 
Moderate 
(diuretic 
unresponsive) 
Albumin (g/dl) >3.5 2.8-3.5 <2.8 
Bilirubin (mg/dl) <2 2-3 >3 
Encephalopathy None Grade 1 and 2 Grade 3 and 4 
Prothrombin time 
INR 
<1.7 1.7-2.3 >2.3 
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Class A: 5-6   survival at one and two year   100% and 65%, Class B: 7-9   
survival at one and two year   80% and 60%, Class C: 10-15 survival 45% 
and 35%. 
MELD SCORING SYSTEM: 
MELD (model for end stage liver disease) was initially developed to assess 
short term prognosis in patients with chronic liver disease who undergo 
TIPS(2,5) (Trans jugular intra-hepatic Porto systemic shunt) but its usefulness 
to assess the prognosis and severity of chronic liver disease has been well 
validated.It consists of three variables 
1) Serum bilirubin 
2) Serum creatinine 
3) Prothrombin time INR(International Normalized Ratio) 
SCORE THREE MONTH MORTALITY (%) 
>40 71.3 
30-39 52.6 
20-29 19.6 
10-19 6 
<9 5 
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MANAGEMENT OF CHRONIC LIVER DISEASE 
GENERAL MANAGEMENT (9): 
As the patient once lands in cirrhosis, liver will never regain its normal 
structure, but symptomatic measures can go a long way in improving the 
quality of life. Liver has such a regenerative capacity that even though 
structurally abnormal its functional capacity may be achieved. 
MANAGEMENT IN A COMPENSATED STATE: 
 Adequate diet (6): 
  30-40 Kcal/kg body weight 
  1.2-1.5g of protein per kg of body weight 
 Abstinence from alcohol. 
 Weight loss if obese. 
 Early detection and treatment of complications. 
 Treatment of specific cause: 
  Antiviral therapy for chronic hepatitis B and C 
  Steroids and immunosuppressant for autoimmune hepatitis. 
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  Ursodeoxycholic acid in early stages of primary biliary 
cirrhosis. 
  Chelation therapy for Wilson’s disease. 
  Venesection for hemochromatosis. 
DECOMPENSATED STATE: 
Treatment is aimed at 
 Identification of precipitating factors 
Early detection and management of complications. 
Hepatic encephalopathy (9): 
 Avoidance of precipitating factors. 
 Lactulose 40-120 ml daily 
 Lactitol 20-40g daily 
 Rifaximin 400mg three times a day. 
 Liver transplantation. 
Portal hypertension: 
 Propranolol 40-80 mg two times a day. 
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Ascites and peripheral edema: 
 Sodium restriction <2 g per day. 
 Fluid restriction if there is Hyponatremia. 
 Spironolactone starting dose 100 mg , maximum dose 400mg per day 
 Furosemide 40 mg per day, maximum 160 mg per day 
 Large volume paracentesis with intravenous salt poor albumin 
Hepatorenal syndrome: 
 Avoidance of nephrotoxins 
 Intravenous albumin 
 Midodrine 
 Octreotide 
Spontaneous bacterial peritonitis 
 Cefotaxime 2 g IV tds 
 Norfloxacin 400 mg twice daily 
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EMERGING ANTIFIBROTIC STRATEGIES: 
 The ever increasing understanding of mechanisms leading to fibro 
genesis has led to development of anti fibrotic therapy a reality in near 
future. The potential approach includes 
 Decrease and or modify host response to stellate cell activation 
 Down regulate stellate cell activation. 
 Stimulate programmed cell death of stellate cell. 
 Increase the degradation of scar matrix. 
ROLE OF LIVER TRANSPLANTATION: 
 Liver transplantation is considered when liver no longer has its ability 
to do its various functions. The following are the most common indication 
for liver transplantation 
 Hepatitis C, B 
 Alcoholic liver disease 
 Autoimmune liver disease 
 Primary biliary cirrhosis 
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 QT DISPERSION 
QT interval: 
 In a standard surface electrocardiogram the QT interval includes the 
QRS complex, ST segment and the T wave corresponding to phases 0 to 3 of 
action potential. 
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QT dispersion: 
QT dispersion has been defined as inter lead variability (difference between 
maximum and minimum QT interval) Increased QT dispersion is a direct 
reflection of disparity in myocardial recovery. Thus determination of QT 
dispersion may help to predict arrthymogenicity in patients with chronic 
liver disease. 
Homogeneity of ventricular recovery is considered to be protective against 
ventricular arrthymias on the contrary dispersion of recovery is considered 
to be arrthymogenic. 
Historical background of QT dispersion: 
  It was in the year 1990, a report was published by Prof 
Campbell et al which re introduced an old concept of inter lead differences 
in QT interval. It was termed “QT dispersion” and it was considered to be an 
index of spatial dispersion of ventricular recovery time. In electrocardiogram 
different leads accentuate the ECG signals of different part of myocardium, 
so that QT dispersion is a mean of heterogeneity of myocardial 
repolarization. Since the idea was first mooted, the cardiology community 
has been flooded with articles measuring and discussing QT dispersion in 
various cardiac and non-cardiac conditions. 
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 Measurement of QT interval (10) and QT dispersion: 
 QT interval is measured from beginning of QRS complex to the end 
of T wave. The presence of a U wave is not included in measuring QT 
interval. 
Corrected QT interval: 
 The QT interval is affected by heart rate.it is longer when the heart 
rate is slow and shorter when the heart rate is fast, so the QT interval should 
be corrected for heart rate. 
 The most frequently used formula for correcting QT interval for heart 
rate is the Bazett’s formula. Corrected QT interval is QT interval (in 
seconds) divided by the square root of preceding RR interval (in seconds) 
 The American college of Cardiology/American Heart Association 
recommendation is that the QT interval should be measured in atleast three 
different leads and longest should be taken as QT interval. 
 Otherwise QT interval should be measured in all the 12 leads and the 
longest value should be taken as the QT interval for that ECG. 
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 PROLONGATION OF QT INERVAL: 
A prolonged QT interval is defined as 
  >0.44 seconds in men 
  >0.46 seconds in women and children 
  >0.50 seconds if there is bundle branch block or intraventricular 
conduction delay. 
The standard method for measuring QT dispersion is to measure QT interval 
in a simultaneous twelve lead ECG recording during a sinus rhythm but 
recording of six or three lead ECG recording is also accepted. 
Various studies have found that QT dispersion varies between 30 and 60 
milliseconds in normal population. A QTcd of more than 70 milliseconds is 
considered abnormal. 
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 CLINICAL APPLICATION OF QT INTERVAL AND QT 
DISPERSION 
QT interval and dispersion were increased in various cardiac and non-
cardiac diseases (13) 
Cardiac diseases: 
 Inherited diseases-congenital long QT syndrome 
 Systemic hypertension 
 Coronary artery disease 
 Acute myocardial infarction 
 Chronic heart failure 
 Hypertrophic obstructive cardiomyopathy 
 Drug induced-antiarrhythmics 
Non-cardiac diseases: 
 Athletes 
 Chronic liver disease 
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 Diabetes mellitus 
 Peripheral vascular disease 
 Chronic obstructive pulmonary artery disease 
CARDIAC DISEASES 
Systemic hypertension: 
QT dispersion is related to resting systolic hypertension but not 
diastolic hypertension. Patients with QT dispersion >80milliseconds are five 
times more likely to die suddenly. 
Coronary artery disease: 
QT dispersion is used to predict cardiac arrhythmias in patients with 
coronary artery disease. 
Acute myocardial infarction: 
It is difficult to measure QT dispersion in patients with acute 
myocardial infarction as electrocardiogram is often abnormal and changes 
rapidly. However increased QT dispersion after myocardial infarction 
predicts ventricular fibrillation. Decrease in QT dispersion following 
reperfusion may indicate that it is successful. 
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QT dispersion may be used to stratify patients with chest pain who are 
at risk for developing acute coronary events. 
Heart failure: 
 Most patients with chronic heart failure die of sudden cardiac death 
and the underlying event is thought to be cardiac arrhythmia which may be 
related to left ventricular systolic function. So QT dispersion could be used 
as a prognostic marker. 
NON-CARDIAC DISEASES 
Sports persons and athletes: 
 QT dispersion is increased in athletes with symptomatic ventricular 
tachycardia, so it is used to identify sports persons at risk of developing 
sudden ventricular tachycardia and sudden death and to identify those with 
undiagnosed hypertropic obstructive cardiomyopathy. 
Diabetes: 
 Diabetes itself is high risk factor for cardiovascular disease and the 
risk is increased many fold if it occurs in the presence of hypertension, 
micro-albuminuria, smoking, hyperlipidemia. QT dispersion can be used to 
predict sudden death in this population. 
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Peripheral vascular disease: 
 QT dispersion is increased in patients with peripheral vascular disease 
even in the absence of overt coronary artery disease. 
Drug induced: 
 Increased QT dispersion has been noted with the use of following 
drugs 
1) Quinidine 
2) Propafenone 
3) Disopyramide 
Beta Blockers have been shown to decrease QT dispersion. 
Recently QT dispersion has been shown to be prolonged in patients with 
chronic obstructive pulmonary disease and Duchene muscular dystrophy. 
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CHRONIC LIVER DISEASE AND QT DISPERSION 
CARDIOVASCULAR CHANGES IN CHRONIC LIVER DISEASE: 
 Cardiovascular changes in chronic liver disease ranges from 
subclinical alterations in early stages to hyper dynamic circulation in 
cirrhotic cardiomyopathy in advanced stages of chronic liver disease. The 
most common electrocardiogram abnormality is prolongation of QT interval 
Previously many studies have proven that chronic liver disease patients have 
increased QT interval and QT dispersion when compared with normal 
population. This particularly holds true for alcoholic liver disease (14)and QT 
interval have been shown to regress following liver transplantation(15,16) The 
cause for this prolongation is unclear. 
There is high risk of cardiac arrhythmias and sudden death in those patients 
whose electrocardiogram shows increased QT interval. 
FACTORS INFLUENCING QT INTERVAL IN CHRONIC LIVER 
DISEASE 
 Autonomic dysfunction 
 Anemia 
 Electrolyte imbalance 
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 Hyperbilirubinemia 
 Hypertestosteronaemia 
QT prolongation is independent of etiology of chronic liver disease but still 
alcoholic etiology has been shown to be clearly associated with prolonged 
QT. 
Relationship between severity and prolongation of QT interval has been 
established that those with severe and advanced liver have increased chance 
of prolonged QT interval. Testosterone has been shown to shorten QT 
interval and as expected in chronic liver disease decrease in testosterone 
leads to prolonged QT interval, and QT dispersion. There are evidence for 
direct relationship between long QT syndrome and sympathetic activity and 
adrenergic hyperactivity has been identified in cirrhosis which leads to 
prolonged QT in these patients. 
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MATERIAL AND METHODS 
SETTING: 
This study was conducted at the Institute of Internal Medicine, Rajiv Gandhi 
Government General Hospital, and Madras Medical College. 
ETHICAL COMMITTEE APPROVAL: 
Obtained. 
STUDY DURATION: 
This study was conducted over a period of six months. 
STUDY POPULATION: 
Patients admitted with chronic liver disease at medical wards, Institute of 
Internal medicine. 
SAMPLE SIZE: 
Sixty cases admitted with chronic liver disease. 
TYPE OF STUDY 
Cross sectional study. 
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 INCLUSION CRITERIA 
 Known case of chronic liver disease 
 Newly detected chronic liver disease 
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 EXCLUSION CRITERIA: 
 Heart failure. 
 Systemic hypertension. 
 Structural heart disease. 
 Coronary artery disease. 
 Arrhythmias and conduction disturbances. 
 Electrolyte abnormalities. 
 Diabetes. 
 Renal and lung diseases. 
 Patients on drugs known to prolong QT interval. 
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DATA COLLECTION AND METHODS 
Informed consent will be obtained from each patient. 
Patients have their history taken according to a Questionnaire and subjected 
to clinical examination. 
Patients are subjected to routine blood investigations like renal function 
tests, liver function tests, PT-INR. 
Chest X-ray, Echocardiography and USG abdomen will be done  
Patients will be classified based on Child-Pugh’s classification. 
Standard 12 lead electrocardiogram will be done for all patients on 
admission. QT interval will be measured manually in all leads and corrected 
by Bazett’s formula. Corrected QT dispersion >70 milliseconds is 
considered abnormal. 
All the data will be entered in proforma(enclosed). 
Data will be analyzed using SPSS package and ANOVA. 
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 OBSERVATION AND RESULTS 
AGE DISTRIBUTION 
AGE GROUP(years) NO OF CASES PERCENTAGES 
30-40 15 25 
41-50 29 48 
51-60 12 20 
>60 4 7 
 
 
 
0
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AGE DISTRIBUTION 
no of cases
53 
 
SEX DISTRIBUTION 
SEX NO OF CASES PERCENTAGES 
MALE 53 88 
FEMALE 7 12 
 
 
 
 
 
 
 
MALES 
88% 
FEMALES 
12% 
SEX DISTRIBUTION 
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CHILD PUGH’S CLASSIFICATION 
CHILD PUGH’S 
CLASS 
NO OF CASES PERCENTAGE 
A 6 10 
B 11 18 
C 43 72 
 
 
 
 
 
10% 
18% 
72% 
CHILD PUGH'S CLASS DISTRIBUTION 
A
B
C
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VIRAL ETIOLOGY: SEX DISTRIBUTION 
VIRAL ETIOLOGY MALE FEMALE 
HEPATITIS B 6 4 
HEPATITIS C 2 1 
 
 
 
 
 
 
 
0
1
2
3
4
5
6
HEPATITIS B
HEPATITIS C
Viral Hepatitis and Gender 
MALE
FEMALE
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VIRAL 
HEPATITIS 
TOTAL NO OF 
CASES 
NO OF CASES 
WITH 
INCREASED QTc 
INTERVAL 
HEPATITIS B 10 6 
HEPATITIS C 3 0 
 
 
 
 
 
 
10 
3 
6 
0 
Hepatitis B HepatitisC
VIRAL ETIOLOGY 
Total no of cases No of cases with increased QTc interval
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VIRAL HEPATITIS TOTAL NO OF 
CASES 
NO OF CASES WITH 
INCREASED QTcd 
HEPATITS B 10 8 
HEPATITS C 3 2 
 
 
 
 
 
 
 
0
2
4
6
8
10
Hepatitis B
Hepatitis C
Viral hepatitis and QTcd 
Total no of cases
No of cases with prolonged
QTcd
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 VIRAL HEPATITS 
 
MEAN QTc INTERVAL( 
in milliseconds) 
 
MEAN QTcd(in 
milliseconds) 
 
HEPATITIS B 
 
450±44.63  79±22.44 
 
HEPATITS C 
 
387±37.98  82±30.11 
 
 
 
 
TOTAL 
BILIRUBIN(mg/dl) 
 
MEAN QTc INTERAVL( 
in milliseconds) 
 
MEAN QT cd(in 
milliseconds) 
 
<2 
 
79.36±24.43  449.94±36.69 
 
2-3 
 
78.5±23.4  429.5±40.69 
 
>3 
 
89.45±20.2  443.12±39.99 
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 TOTAL 
BILIRUBIN(mg/dl) 
 
TOTAL NO OF CASES 
 
NO OF CASE WITH 
PROLONGED QTc 
INTERVAL 
 
<2 
 
19 
 
10 
 
2-3 
 
8 
 
2 
 
>3 
 
33 
 
17 
 
SERUM BILIRUBIN AND QTC INTERVAL 
 
0
5
10
15
20
25
30
35
<2 2-3 >3
Total no of case
No of cases with prolonged QTc
interval
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 TOTAL 
BILIRUBIN(mg/dl) 
 
TOTAL NO OF CASES 
 
NO OF CASE WITH 
INCREASED QTc d 
 
<2 
 
19 
 
14 
 
2-3 
 
8 
 
5 
 
>3 
 
33 
 
29 
 
 
<2
2-3
>3
19 
8 
33 14 
5 
29 
Serum bilirubin and QTcd 
Total no of cases No of cases with increased QTcd
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 PT-INR 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
PROLONGED QTc 
INTERVAL 
 
<1.7 
 
20 
 
6 
 
1.7-2.3 
 
36 
 
20 
 
>2.3 
 
4 
 
3 
 
 
 
 
<1.7
1.7-2.3
>2.3
20 
36 
4 
6 
20 
3 
PT-INR and QTc interval 
No of cases with prolonged QTc interval Total no of cases
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 PT-INR 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
INCREASED QTcd 
 
<1.7 
 
20 
 
12 
 
1.7-2.3 
 
36 
 
33 
 
>2.3 
 
4 
 
4 
 
 
0 10 20 30 40
<1.7
1.7-2.3
>2.3
PT-INR AND QTcd 
No of cases with increased QTcd
Total no of cases
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 PT-INR 
 
MEAN QTc 
INTERVAL(ms) 
 
MEAN QT cd(ms) 
 
<1.7 
 
429.6±37.06  72.1±24.06 
 
1.7-2.3 
 
448.47±38.88  91.41±19.06 
 
>2.3 
 
467.75±32.93  88.75±11.87 
 
 
 
SERUM ALBUMIN(g/l) 
 
MEAN QT c 
INTERVAL(ms) 
 
MEAN QT cd(ms) 
<2.8 425.5±39.01 90.42±21.17 
2.8-3.5 457.16±33.59 89.04±21.89 
>3.5 449.85±39.56 68.78±17.16 
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 SERUM ALBUMIN(g/l) 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
INCREASED QTc 
INTERVAL 
<2.8 21 6 
2.8-3.5 25 17 
>3.5 14 6 
 
 
 
 
>2.8 2.8-3.5 >3.5
21 
25 
14 
6 
17 
6 
Serum albumin and QTc interval 
TOTAL NO OF CASES NO OF CASES WITH INCREASED QT c INTERVAL
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SERUM 
ALBUMIN(g/l) 
 
TOTAL NO OF 
CASES(ms) 
 
NO OF CASES WITH 
INCREASED QTcd(ms) 
<2.8 21 19 
2.8-3.5 25 21 
>3.5 14 4 
 
 
 
 
21 
25 
14 
19 
21 
9 
>2.8 2.8-3.5 >3.5
serum albumin and QTcd 
TOTAL NO OF CASES NO OF CASES WITH INCREASED QT cd
66 
 
 HYPOGONA 
DISM 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
PROLONGED QTc 
INTERVAL 
 
YES 
 
37 
 
18 
 
NO 
 
16 
 
6 
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Hypogonadism and QTc interval 
Total no of cases
No of cases with increased QTc
interval
67 
 
 HYPOGONADISM 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
INCREASED QTcd 
 
YES 
 
37 
 
32 
 
NO 
 
16 
 
9 
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Hypogonadism and QTcd 
Total no of cases No of cases with increased QTcd
68 
 
 HYPOGONADISM 
 
MEAN QTc INTERVAL(in 
ms) 
 
MEAN QTcd(in ms) 
 
YES 
 
445.13±39.23 
 
88.35±20.66 
 
NO 
 
437.93±32.02 
 
76.75±27.12 
 
 
 
 
H/O ALCOHOLISM 
 
MEAN QTc INTERVAL(in 
ms) 
 
MEAN QTcd(in ms) 
 
YES 
 
446±35.98  86.5±21.82 
 
NO 
 
424±56.46  71.57±21.7 
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 ALCOHOLISM 
 
TOTAL NO CASES 
 
NO OF CASES WITH 
PROLONGED QTc 
INERVAL 
 
YES 
 
53 
 
26 
 
NO 
 
7 
 
3 
 
 
 
 
 
53 
7 
26 
3 
yes
no
Alcoholism and QTc interval 
No of cases with increased QTc interval Total no of cases
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 ALCOHOLISM 
 
TOTAL NO CASES 
 
NO OF CASES WITH 
INCREASED QTcd 
 
YES 
 
53 
 
43 
 
NO 
 
7 
 
5 
 
 
 
 
 
yes no
53 
7 
43 
5 
Alcoholism and QTcd 
Total no of cases No of cases with increased QTcd
71 
 
 SEX 
 
TOTAL NO OF CASES 
 
H/O ALCOHOLISM 
 
MALES 
 
53 
 
50 
 
FEMALES 
 
7 
 
3 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
MALES FEMALES
GENDER AND ALCOHOLISM 
TOTAL NO OF CASES
H/O ALCOHOLISM
72 
 
  
HEPATIC 
ENCEPHALOPATHY 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
PROLONGED QTcd 
 
GRADE 0 
 
11 
 
6 
 
GRADE1,2 
 
46 
 
39 
 
GRADE3,4 
 
3 
 
3 
 
 
 
Grade 0
Grade1,2
Grade3,4
11 
46 
3 
6 
39 
3 
Hepatic encephalopathy and QTcd 
Total no of cases No of cases with prolonged QTc interval
73 
 
 HEPATIC 
ENCEPHALOPATHY 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
INCREASED QTc 
INTERVAL 
GRADE 0 11 5 
GRADE1,2 46 23 
GRADE3,4 3 1 
 
 
 
 
 
Grade 0 Grade1,2 Grade3,4
11 
46 
3 5 
23 
1 
Hepatic encephalopathy and QTc Interval 
Total no of cases No of cases with prolonged QTc interval
74 
 
 HEPATIC 
ENCEPHALOPATHY 
MEAN QTC INTERVAL( 
in milliseconds) 
MEAN QTcd( in 
milliseconds) 
 
GRADE 0 
 
448.9±37.22 
 
81.27±31.93 
 
GRADE1,2 
 
444.82±37.04 
 
85.93±20.26 
 
GRADE3,4 
 
402.66±64.59 
 
80.33±6.11 
 
 
 
DURATION OF 
ALCOHOL 
INTAKE(years) 
 
MEAN QTc INTERVAL( 
in ms) 
 
MEAN QTcd(in ms) 
 
<10 
 
444.15±36.55  89.2±18.10 
 
>10 
 
447±36.16  84.93±23.93 
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 DURATION OF 
ALCOHOL 
INTAKE(years) 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
PROLONGED QTc 
INTERVAL 
 
<10 
 
20 
 
9 
 
>10 
 
33 
 
17 
 
 
 
0
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35
<10 yrs > 10 yrs
Duration of alcoholism and QTc interval 
Total no of cases
No of cases with prolonged QTc
interval
76 
 
 DURATION OF 
ALCOHOL 
INTAKE(years) 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
INCREASED QTcd 
 
<10 
 
20 
 
17 
 
>10 
 
33 
 
26 
 
 
 
<10 yrs > 10 yrs
20 33 
17 26 
Duration of alcoholism and QTcd 
Total no of cases No of cases with prolonged QTcd
77 
 
CHILD PUGH’S CLASS TOTAL NO OF CASES NO OF CASES WITH 
PROLONGED QTc 
INTERVAL 
 
A 
 
6 
 
0 
 
B 
 
11 
 
7 
 
C 
 
43 
 
22 
 
 
  
0
10
20
30
40
50
A
B
C
 Child Pugh's class and QTc interval 
Total no of Cases
No of cases with prolonged QTc
interval
78 
 
  
CHILD PUGH’S CLASS 
 
TOTAL NO OF CASES 
 
NO OF CASES WITH 
INCREASED QTcd 
A 6 1 
B 11 8 
C 43 39 
 
 
 
  
6 
11 
43 
1 
8 
39 
A B C
Child Pugh's class and QTcd 
Total no of cases No of cases with increased QTcd
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CHILD PUGH’S CLASS MEAN QTc INTERVAL(in 
milliseconds) 
MEAN QTcd(in 
milliseconds) 
A 415±4.92 54.66±19.85 
B 457±36.53 74.36±16.69 
C 443.88±40.6 91.67±11.25 
Multiple Comparison:Dependent Variable: QT cd  
Tukey HSD  
(I) Child pugh 
class 
(J) Child pugh 
class Std. Error Sig. 95% Confidence Interval 
        Lower Bound 
Upper 
Bound 
A B 9.562 .107 -42.71 3.31 
  C 8.211 .000 -56.86 -17.34 
B A 9.562 .107 -3.31 42.71 
  C 6.366 .022 -32.72 -2.08 
C A 8.211 .000 17.34 56.86 
  B 6.366 .022 2.08 32.72 
*  The mean difference is significant at the .05 level. 
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RESULTS 
Age distribution: 
 In this present study about 25% were in the age group 30-40 years, 
48% were in the age group of 41-50 years, 20% were in the age group of 51-
60 years and 7% were in the group of >61 years. The mean age is 
46.56±7.5years 
Sex and QTcd: 
  In our study about 88% were males and 12% were females. About 
77% of males had increased QTcd and mean QTcd is 84.84ms. All of the 
female patients had prolonged QTcd and the mean QTcd is 84.42ms. 
Viral hepatitis: 
 Hepatitis B was positive in 17% of cases and Hepatitis C was positive 
in 6% of cases. Among those with Hepatitis B 80% had increased QTcd and 
the mean QTcd was 79±22.44. 66% of those with hepatitis C had increased 
QTcd and the mean QTcd was 82ms. 
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Serum bilirubin QTcd: 
  Out of 60 patients serum bilirubin was <2 in 19 patients, 
between 2-3 in 8 patients and >3 in 33 patients. 74 % of those with bilirubin 
had increased QT interval and the mean QTcd in them was 79.36ms. 63% of 
those with serum bilirubin between 2-3 had increased QTcd ant the mean 
QTcd was 78.5ms. 88% of those with serum bilirubin >3 had prolonged 
QTcd and their mean QTcd was 89.45ms. 
Serum albumin and QTcd: 
  Out 60 patients 21 had serum albumin below 2.8 g/dl, 90 % of 
them had prolonged QTcd and their mean QTcd was 90.42ms. 25 patients 
had albumin level between 2-3, 84 % of them had increased QTcd and their 
mean was 89.14ms. 14 patients had serum albumin >3 , 64% of them had 
increased QTcd and their men was 68.78ms. 
Hypogonadism: 
  Out of 60 patients, 37 had features of Hypogonadism, 86% of 
these had prolonged QTcd and their mean QTcd was 88.35ms. About 56% 
of those without hypogonadism had increased QTcd and the mean QTcd was 
76.75ms. 
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Alcoholism and QTcd: 
 In this present study, 88% were alcoholic and 12% were nonalcoholic. 
Among those with alcoholism 81% had prolonged QTcd and their mean 
QTcd was 86.5 ms, while 71% of those without alcoholism had increased 
QTcd and their mean QTcd was 71.57ms. 
Child Pugh’s class and QTcd: 
  In this study 10% of patients were in Child Pugh’s class A, 18% 
were in Child Pugh’s class B and 72% belonged to Child Pugh’s class C. 
Increased QTcd was noted in 17% of those in Child Pugh’s class A, 73% of 
those in Child Pugh’s class B, 91% of those in Child Pugh’s class C. The 
mean QTcd in A, B, C class were as follows 66ms, 74.36ms, 91.67ms. and 
the difference between classA and B, C was statistically significant as shown 
by ANOVA. 
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DISCUSSION 
Number of patients taken up for study: 
Study groups Total number of cases 
Bernadi et al 94 
Mozos et al 38 
Kosar et al 33 
Present study 60 
 
But no controls were used in this present study. 
AGE: 
Mean age of patients in various studies 
Kosar et al  53±11years 
Bernardi et al  53.1±1.4years 
Present study 46.5±7.5years 
The mean age of patients in this present study was lower than that of 
previous studies. 
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Mean QTc interval and QTcd: 
Study group Mean QTc interval(in 
milliseconds) 
Mean QTcd(in 
milliseconds) 
Bernardi et al 462±4.2 - 
Kosar et al 448±96 71±39 
Present study 443.5±38.9 84.8±22 
 
In this present study QTcd is higher than previous studies, while QTc 
interval though prolonged is lower than previous studies. 
Etiology and QT variables: 
Mean QTc interval in alcoholics was 527±50 ms in a study by Kosar et al, 
while it is 446±35.98 ms in our study. And our study showed difference in 
mean QTcd between alcoholics and non-alcoholics 
  Alcoholics:        446±35.9 ms 
  Non alcoholics: 424±56.4 ms 
But this was not statistically significant p value 0.161. 
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The mean QTc interval among patients with viral etiology 
Mozos et al   481±57ms 
Present study  418.5±44ms 
Our study has lower mean QTc interval than previous study 
Child Pugh’s class and QT variables: 
Child Pugh’s class 
Study group A B C 
Genovesi et al 425±24 452±30 465±24 
Mozos et al 462±25 493±62 520±45 
Kosar et al 437±49 444±40 468±66 
Present study 415±4.9 457±36.5 443.8±40.6 
 
In this present study QTc interval was increased in both child Pugh’s class B 
and C, but was less than 440ms in class A as was the results of Genovesi et 
al and Kosar et al. 
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Many studies had previously demonstrated prolonged QT variables in 
patients with alcoholic liver disease and child Pugh’s class C (7). In this 
present study though mean QT variables were increased among alcoholics it 
was not statistically significant as was the result with Bernardi et al.  
Mean QTcd (in milliseconds) 
Child Pugh’s class 
Study group A B C 
Kosar et al 65±33 67±24 83±43 
Present study 54.7±19.9 74.4±16.7 91.7±19.2 
 
QT variables were significantly increased in class B and C when compared 
with class A, as shown by ANOVA , as was the findings of Bernardi et al, 
Kosar et al, Mozos et al. 
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LIMITATIONS OF STUDY 
 One limitation of this study is low number of female patients, patients 
with nonalcoholic etiology, and the results should be confirmed in 
large group of patients. 
 Bazett’s formula was used to correct QT interval, it may under correct 
if heart rate is lower than 60 and over correct if heart rate is more than 
110. 
 Though thorough history, physical examination, ECG and 
echocardiogram were done to rule out coronary artery disease, 
coronary angiogram was not done to rule out occult coronary artery 
disease. 
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CONCLUSION 
 QTcd (corrected QT dispersion) correlates well with the severity of 
chronic liver disease based on Child Pugh’s class. 
 QTcd is independent of etiology of chronic liver disease. 
 QTcd can be used to assess the severity of chronic liver disease. 
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PROFORMA 
CORRECTED QT DISPERSION AND ITS CORRELATION WITH 
SEVERITY OF CHRONIC LIVER DISEASE 
Name :      Patient ID No: 
Age/Sex : 
IP No : 
Patient characteristics Drugs 
Duration of CLD   Antibiotics 
 Smoking  Furosemide 
 Alcoholism  Spironolactone 
  Propranolol 
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CLINICAL PARAMETERS 
Pulse  Blood Pressure  
 Pallor  Ascites 
 Icterus  Dilated veins over the abdomen 
 Oedema  Splenomegaly 
 Features of hypogonadism  Hepatic flap 
 
Investigations: 
RFT LFT 
Glucose  mg/dl Total bilirubin  mg/dl 
Urea  mg/dl Direct bilirubin  mg/dl 
Creatinine  mg/dl SGOT  U/l 
Na+  mEq/l SGPT  U/l 
K+  mEq/l ALP  U/l 
HBsAg  Total protein  g/dl 
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Anti-HCV  Albumin  g/dl 
Chest X-ray: 
 
 
Echocardiography: 
 
 
Ultrasound abdomen: 
 
ECG: 
Heart rate  
QTc max  
QTc min  
QTcd  
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Child-Pugh classification 
Parameter 1 2 3 
Ascites    
Bilirubin (mg/dL)    
Albumin (g/dL)    
PT-INR    
Encephalopathy    
GRADE  
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PATIENT CONSENT FORM 
Study Detail : Corrected QT dispersion and its correlation with 
severity of chronic liver disease 
Study Centre : Rajiv Gandhi Government General Hospital, 
Chennai. 
Patient’s Name :  
Patient’s Age :  
Identification 
Number 
:  
Patient may check (☑) these boxes 
I confirm that I have understood the purpose of procedure for the above 
study. I have the opportunity to ask question and all my questions and 
doubts have been answered to my complete satisfaction.  
I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time without giving reason, without my legal 
rights being affected.  
102 
 
I understand that sponsor of the clinical study, others working on the 
sponsor’s behalf, the ethical committee and the regulatory authorities 
will not need my permission to look at my health records, both in 
respect of current study and any further research that may be conducted 
in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any 
information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that 
arise from this study.  
I agree to take part in the above study and to comply with the 
instructions given during the study and faithfully cooperate with the 
study team and to immediately inform the study staff if I suffer from 
any deterioration in my health or wellbeing or any unexpected or 
unusual symptoms.  
I hereby consent to participate in this study.  
I hereby give permission to undergo complete clinical examination and 
diagnostic tests including haematological, biochemical, radiological 
tests.  
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Signature/thumb impression                                Signature of Investigator 
Patient’s Name and Address:                               Study Investigator’s Name: 
                                                                              Dr. A. VIGNESH 
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